Reportlinker Adds Global Vaccine Market Forecast to 2012

Oct 07, 2010, 13:54 ET from Reportlinker

NEW YORK, Oct. 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Vaccine Market Forecast to 2012

http://www.reportlinker.com/p0305645/Global-Vaccine-Market-Forecast-to-2012.html

The prevalence of infectious and non-infectious diseases has significantly risen worldwide, leading to a spur in healthcare expenditure of both the developed and developing countries. Vaccine represents one of the most attractive and fast growing sectors, with players' revenue exceeding their expectations. Apart from the high disease prevalence, growing population and emergence of new pandemics are important growth drivers of the global vaccine market.

According to our new research report "Global Vaccine Market Forecast to 2012", the market for adult vaccines has been growing at faster rate than pediatric vaccines. The rising prevalence of life threatening diseases such as cancer and HIV is the prominent factor driving growth in the adult vaccine segment. A number of healthcare companies are focusing on cancer vaccine development process so that they can enhance their profit. The cancer vaccine market is expected to grow at a CAGR of 25% during 2009-2012 on the back of government support and rising participation of private players.

Our analysis of the global vaccine market with emphasis on the country level illustrates that the fast developing countries such as India and China will raise their overall share. Currently, these countries have been actively participating in market activities and vaccine manufacturers are booking profits on their sales. Besides, other countries will facilitate the development of vaccine market in their respective places in order to minimize health problems.

The report is an outcome of extensive research and objective analysis of the vaccine market in key countries of the world. It identifies all the necessary factors and aspects related to market and represent current industry status with future forecast on vaccine types and countries for 2009-2012. In addition, the description of key players and their recent activities have been provided to showcase an effective and balanced outlook of the global vaccine market.

1. Analyst View

2. Research Methodology

3. Market Overview

4. Key Market Drivers

4.1 Improved Routine Immunization

4.2 New Vaccine Introduction

4.3 High Investments

4.4 Support from Government and NGOs

5. Emerging Trends

5.1 Cancer Vaccines: Gaining Popularity

5.2 Collaborations in Vaccine Industry

5.3 Grants: Raising Support

6. Industry Performance and Future Trends

7. Major Vaccine Segments

7.1 Basic Pediatrics

7.2 Enhanced Pediatrics

7.3 Proprietary Pediatrics

7.4 Adult Vaccines

8. Pediatric Vaccines

8.1 Pneumococcal

8.2 Polio

8.3 Varicella

8.4 Meningococcal

8.5 Rotavirus

8.6 DTP

8.7 Measles, Mumps & Rubella (MMR)

8.8 Tuberculosis

9. Adult/Travel & Therapeutic Vaccines

9.1 Hepatitis B

9.2 Malaria

9.3 Yellow Fever

9.4 Rabies

9.5 Japanese Encephalitis

9.6 Typhoid

9.7 West Nile

9.8 HIV

9.9 Cancer

9.10 Influenza

10. Key Geographical Markets

10.1 US

10.1.1 Market Overview

10.1.2 Key Players

10.1.3 Product Portfolio

10.2 Europe

10.2.1 Market Overview

10.2.2 Key Players

10.2.3 Product Portfolio

10.3 China

10.3.1 Market Overview

10.3.2 Key Players

10.3.3 Product Portfolio

10.4 India

10.4.1 Market Overview

10.4.2 Key Players

10.4.3 Product Portfolio

10.5 Japan

10.5.1 Market Overview

10.5.2 Key Players

10.5.3 Product Portfolio

10.6 Brazil

10.6.1 Market Overview

10.6.2 Key Players

10.6.3 Product Portfolio

11. Investment Risk in Vaccine Industry

11.1 High R&D Cost

11.2 Lack of Infrastructure for Trials and Manufacturing

11.3 Vaccine Supply

11.4 Ineffective Distribution

12. Key Mergers & Acquisitions

13. Key Vaccine Brands Forecast to 2012

14. Competitive Landscape

14.1 Vaccine Majors

14.1.1 Sanofi-Aventis

14.1.2 Novartis

14.2 Biotech-focused Vaccine Companies

14.2.1 GSK

14.2.2 Pfizer

14.3 Domestic-focused Vaccine Companies

14.3.1 Merck & Co.

List of Figures:

Figure 4-1: Global - Vaccine Market by Source of Funding (%), 2005 to 2010

Figure 6-1: Global - Vaccine Market (Billion US$), 2009-2012

Figure 7-1: Global - Basic Pediatric Vaccine Market (Million US$), 2007-2012

Figure 7-2: Global - Enhanced Pediatric Vaccine Market (Billion US$), 2007-2012

Figure 7-3: Global - Proprietary Pediatric Vaccine Market (Billion US$), 2007-2012

Figure 7-4: Global - Share of Adult Vaccine Sales in Vaccine Market (2008 & 2009)

Figure 7-5: Global - Adult Vaccine Market (Billion US$), 2009-2012

Figure 8-1: Global - Pneumococcal Vaccine Market (Billion US$), 2009-2012

Figure 8-2: Global - Number of Polio Incidences (2007-2009)

Figure 8-3: Global - Polio Vaccine Market (Million US$), 2004 & 2011

Figure 8-4: Global - Varicella Vaccine Market (Million US$), 2007 & 2008

Figure 8-5: Global - Meningococcal Vaccine (Million US$), 2009 & 2013

Figure 8-6: Global - Rotavirus Vaccine Market (Million US$), 2009 & 2010

Figure 8-7: Global - Rotavirus Vaccine Market by Region (%), 2010

Figure 8-8: Global - Number of Diphtheria Incidences by Region (2008)

Figure 8-9: Global - Number of Pertussis Incidences by Region (2008)

Figure 8-10: Global - Number of nTetanus Incidences by Region (2008)

Figure 8-11: Global - Number of tTetanus Incidences by Region (2008)

Figure 8-12: Global - Number of Measles Incidences by Region (2008)

Figure 8-13: Global - Number of Mumps Incidences by Region (2008)

Figure 8-14: Global - Number of Rubella Incidences by Region (2008)

Figure 8-15: Global - Number of Tuberculosis Incidences by Region ('000), 2008

Figure 9-1: Global - Hepatitis B Surface Antigen Prevalence (%), 2006

Figure 9-2: Global - Hepatitis B Vaccine Market (Billion US$), 2009-2012

Figure 9-3: Global - Yellow Fever Vaccine Market (Million US$), 2010 & 2013

Figure 9-4: Global - Japanese Encephalitis Market (Million US$), 2009-2012

Figure 9-5: Global - R&D Investment in AIDS Vaccine Development (Million US$), 2006-2009

Figure 9-6: Global - Sources for Funding in HIV Vaccine R&D (%), 2009

Figure 9-7: Global - Cancer Vaccine Market (Billion US$), 2009-2012

Figure 9-8: Global - Number of Cancer Vaccines in Various Phases of Clinical Developments by Type (Aug 2005)

Figure 9-9: Global - Seasonal Influenza Vaccine Market (Billion US$), 2009-2012

Figure 10-1: Global - Vaccine Market by Region (%), 2009

Figure 10-2: Global - Forecast for Vaccine Market by Region (%), 2012

Figure 10-3: US - Vaccine Market (Billion US$), 2008-2012

Figure 10-4: US - Pediatric Vaccine Market (Billion US$), 2010-2012

Figure 10-5: US - Hepatitis Vaccine Market (Billion US$), 2009-2012

Figure 10-6: US - Influenza Vaccine Production by Player (%), 2009

Figure 10-7: US - Influenza Vaccine Production and Consumption (Million Doses), 2004-2005 to 2008-2009

Figure 10-8: US - Influenza Vaccine Sales by Provider (%), 2007-2008

Figure 10-9: US - Influenza Vaccine Market (Million US$), 2009-2012

Figure 10-10: US - Travel Vaccine Market (Million US$), 2009-2012

Figure 10-11: US - Developmental Vaccine Market (Million US$), 2009-2012

Figure 10-12: Europe - Vaccine Market (Billion US$), 2009-2012

Figure 10-13: Europe - Share of Key Players in Vaccine Market (2008)

Figure 10-14: China - Vaccine Market (Billion US$), 2008-2012

Figure 10-15: China - Share of Key Players in Vaccine Market (2008)

Figure 10-16: China - Influenza Vaccine Market (Million US$), 2008-2012

Figure 10-17: India - Share of Domestic Consumption and Exports in Vaccine Market (2009)

Figure 10-18: India - Share of Private Sector in Domestic Vaccine Market (2008)

Figure 10-19: India - Vaccine Market (Million US$), 2008-09 to 2011-12

Figure 10-20: India - Share of Key Players in Vaccine Market (2006-07)

Figure 10-21: Japan - Vaccine Market (Billion US$), 2008-2012

Figure 10-22: Japan - Influenza Vaccine Production (Million Doses), 2007-08 & 2008-09

Figure 10-23: Japan - Share of Domestic and Foreign Players in Vaccine Market (2009)

Figure 10-24: Japan - Vaccine Market by Segment (%), 2009

Figure 10-25: Brazil - Vaccine Market (Billion BRL), 2009-2012

Figure 10-26: Brazil - Share of Public and Private Sector in Vaccine Market (2004)

Figure 10-27: Brazil - Share of Key Players in Private Sector Vaccine Market (2008)

Figure 11-1: Global - Dose Consumption and Revenue by Regional Income (%), 2005

Figure 14-1: Global - Vaccine Market by Player (%), 2009

List of Tables:

Table 8-1: Global - Pneumococcal Vaccine Supply

Table 8-2: Global - Leading DTP Vaccine Brands (Million US$), 2008

Table 8-3: Global - Leading MMR Vaccine Brands (Million US$), 2008

Table 9-1: Global - Number of HIV/AIDS Patients by Region (2008)

Table 9-2: US - Number of New Cancer Cases and Deaths (2009)

Table 9-3: Global - Five Year Relative Survival Rates by Stage of Cancer Diagnosis (%)

Table 9-4: Global - List of Launched and Under-development Cancer Vaccines by Indication

Table 9-5: Global - Top 5 Companies' Pandemic Influenza (H1N1) Vaccine Sales (Million US$), 2009

Table 10-1: China - Number of Reported Cases of Diseases Preventable by Vaccine (2008 & 2009)

Table 10-2: China - Vaccine Classification

Table 10-3: China - Annual Pediatric Vaccine Doses Requirement (Million)

Table 10-4: China - Revenues of Some Vaccine Manufacturing Biological Companies (Million RMB), 2006

Table 10-5: India - Sales of Top Five Vaccine Companies (Million US$), 2008-09

Table 10-6: Japan - Sales of Top Domestic Vaccine Manufacturers (Million JPY)

Table 10-7: Japan - Sales of Top Foreign Vaccine Players (Million JPY)

Table 10-8: Brazil - Public and Private Sector Vaccine Market (Million BRL)

Table 11-1: Health Statistics in Developed and Developing Countries (%)

Table 12-1: Global - Key Mergers & Acquisitions in Vaccine Market (2005 to 2009)

Table 13-1: Global - Top Launched Vaccine Brand Sales (Billion US$), 2009 & 2012

Table 13-2: Global - Forecast for Top Vaccine Brand Sales Under-development (Million US$), 2012

Table 14-1: Sanofi Aventis - Strengths and Weaknesses

Table 14-2: Novartis - Strengths and Weaknesses

Table 14-3: GSK - Strengths and Weaknesses

Table 14-4: Pfizer - Strengths and Weaknesses

Table 14-5: Global - Major Vaccine Companies (Segmentation by Revenue)

To order this report:

Biopharmaceutical Industry: Global Vaccine Market Forecast to 2012

Biopharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com